Abstract
Stimulating cardiac β1-adrenoceptors with oxyfedrine causes dilatation of coronary vessels and positive inotropic effects on the myocardium. β1-adrenergic agonists increase coronary blood flow in nonstenotic and stenotic vessels.
The main indication for the use of the phosphodiesterase inhibitors pamrinone, mirinone, enoximone and piroximone is acute treatment of severe congestive heart failure. Theophylline is indicated for the treatment of asthma, chronic obstructive pulmonary disease, apnea in preterm infants ans sleep apnea syndrome.
Severe arterial occlusive disease associated with atherosclerosis can be beneficially affected by elcosanoids. These drugs must be administered parenterally and have a half-life of only a few minutes.
Sublingual or buccal preparations of nitrates are the only prompt method (within 1 or 2 min) of terminating anginal pain, except for biting nifedipine capsules. The short half-life (about 2.5 min) of nitroglycerin (glyceryl trinitrate) makes long term therapy impossible. Tolerance is a problem encountered with longer-acting nitric oxide donors.
Knowledge of the pharmacokinetic properties of vasodilating drugs can prevent a too sudden and severe blood pressure decrease in patients with chronic hypertension. In considering the administration of a second dose, or another drug, the time necessary for the initially administered drug to reach maximal efficacy should be taken into account.
In hypertensive emergencies urapidil, sodium nitroprusside, nitroglycerin, hydralazine and phentolamine are the drugs of choice, with the addition of β-blockers during catecholamine crisis or dissecting aortic aneurysm.
Childhood hypertension is most often treated with angiotensin-converting enzyme (ACE) inhibitors or calcium antagonists, primarily nifedipine. Because of the teratogenic risk involved with ACE inhibitors, extreme caution must be exercised when prescribing for adolescent females.
The propagation of health benefits to breast-fed infants, combined with more women delaying pregnancy until their fourth decade, has entailed an increase in the need for hypertension management during lactation. Low dose hydrochlorothiazide, propranolol, nifendipine and enalapril or captopril do not pose enough of a risk to preclude breastfeeding in this group.
The most frequently used antihypertensive agents during pregnancy are methyldopa, labetalol and calcium channel antagonists. Methyldopa and β-blockers are the drugs of choice for treating mild to moderate hypertension. Prazosin and hydralazine are used to treat moderate to severe hypertension and hydralazine, urapidil or labetalol are used to treat hypertensive emergencies. The use of overly aggressive antihypertensive therapy during pregnancy should be avoided so that adequate uteroplacental blood flow is maintained. Methyldopa is the only drug accepted for use during the first trimester of pregnancy.
Similar content being viewed by others
References
Cambridge D, Davey MJ, Massingham R. Prazosin, a selective antagonist of postsynaptic α-adrenoreceptors. Br J Pharmacol. 1977; 59: 514–5.
Graham RM, Pettinger WA. Prazosin. N Engl J Med. 1979; 300: 232–6.
Pierpont GL, Franciosa JA, Cohn JN. Effect of prazosin on renal function in congestive heart failure. Clin Pharmacol Ther. 1980; 28: 335–9.
Walker RG, Whitworth JA, Saines D, et al. Prazosin: long term treatment of moderate and severe hypertension and lack of tolerance. Med J Aust. 1981; 2: 146–7.
Jansen H, Baggen RG. Effects of doxazosin and propranolol administration on lipoprotein lipases in cholesterol-fed rats. J Cardiovasc Pharmacol. 1987; 10 Suppl. 9: 16–20.
Dzau VJ. Factors influencing the lipid response to selective alpha-1 inhibition. J Cardiovasc Pharmacol. 1989; 13 Suppl. 2: 50–2.
Huupponen R, Lehtonen A, Vahatalo M. Effect of doxazosin on insulin sensitivity in hypertensive non-insulin dependent diabetic patients. Eur J Clin Pharmacol. 1992; 43: 365–8.
Schaefer SG, Kaan EC, Christen MO, et al. Why imidazoline receptor modulator in the treatment of hypertension? Ann N Y Acad Sci. 1995; 763: 659–72.
Mitrovic V, Patyna WD, Hitting J, et al. Hemodynamic and neurohumoral effects of moxonidine in patients with essential hypertension. Cardiovasc Drugs Ther. 1991; 5: 967–72.
Ernsberger P, Damon TH, Graff LM, et al. Moxonidine, a centrally acting antihypertensive agent, is a selective ligand for I1-imidazoline sites. J Pharmacol Exp Ther. 1993; 264: 172–82.
Molderings GJ, Göthert M, Christen O, et al. Imidazolrezeptoren: Angriffsort einer neuen Generation von antihypertensiven Arzneimitteln. Dtsch Med Wochenschr. 1992; 117: 67–71.
Carruthers SG. Adverse effects of alpha 1-adrenergic blocking drugs. Drug Saf. 1994; 11: 12–20.
Lipson LG, Moore D, Pope AM, et al. Sexual dysfunction in hypertensive diabetic men. J Cardiovasc Med Special 1981; Suppl: 30–7.
Stanaszek WF, Kellerman D, Brogden RN, et al. Prazosin update: a review of its pharmacological properties and therapeutic use in hypertension and congestive heart failure. Drugs. 1983; 25: 339–84.
Vincent J, Meredith PA, Reid JL, et al. Clinical pharmacokinetics of prazosin. Clin Pharmacokinet. 1985; 10: 144–54.
Arnold SB, Williams RL, Ports TA, et al. Attenuation of prazosin effect on cardiac output in chronic heart failure. Ann Intern Med. 1979; 91: 345–9.
Desch CE, Magorien RD, Triffon DW, et al. Development of pharmacodynamic tolerance to prazosin in congestive heart failure. Am J Cardiol. 1979; 44: 1178.
Elkayam U, Lejemtel TH, Mathur M, et al. Marked early attenuation of hemodynamic effects of oral prazosin therapy in chronic congestive heart failure. Am J Cardiol. 1979; 44: 540–5.
Goldman SA, Johnson LL, Escala E, et al. Improved exercise ejection fraction with long-term prazosin therapy in patients with heart failure. Am J Med. 1980; 68: 36–42.
Bertel O. Long-term therapy with prazosin in severe chronic congestive heart failure. Cardiology. 1980; 65 Suppl. 1: 70–3.
Feldman RC, Ball RM, Winchester MA, et al. Beneficial hemodynamic response to chronic prazosin therapy in congestive heart failure. Am Heart J. 1981; 101: 534–40.
Mason DT, Awan NA, DeMaria AN. Afterload reduction in the management of congestive heart failure. Hosp Formul. 1979; 14: 641–52.
Massie B, Chan S. Management of hypotension in patients with congestive heart failure: results of treatment with prazosin. J Cardiovasc Med 1981; Suppl: 60–8.
Davey DA, Dommisse J. The management of hypertension in pregnancy. S Afr Med J. 1980; 58: 551–6.
Welt SI, Dorminy JH, Jelovsek FR, et al. The effect of prophylactic management and therapeutics on hypertensive disease in pregnancy: preliminary studies. Obstet Gynaecol. 1981; 57: 557–65.
McNeil JJ, Drummer OH, Conway REL, et al. Effect of age on pharmacokinetics of and blood pressure responses to praxosin and terazosin. J Cardiovasc Pharmacol. 1987; 10: 168–75.
Andros E, Detmar-Hanna D, Suteparuk S, et al. The effect of aging on the pharmacokinetics and pharmacodynamic s of prazosin. Eur J Clin Pharmacol. 1996; 50: 41–6.
Hunt BA, Self TH, Lalonde RL, et al. Calcium channel blockers as inhibitors of drug metabolism. Chest. 1989; 96: 393–9.
Fulton BF, Wagstaff AJ, Sorkin EM. Doxazosin: an update of its clinical pharmacology and therapeutic applications in hypertension and benign prostatic hyperplasia. Drugs. 1995; 49(2): 295–320.
Elliott HL, Meredith PA, Reid JL. Pharmacokinetic overview of doxazosin. Am J Cardiol. 1987; 59: 78G–81G.
Scott PJW, Hosie J, Scott MGB. A double-blind and cross-over comparison of once daily doxazosin and placebo with steadystate pharmacokinetics in elderly hypertensive patients. Eur J Clin Pharmacol. 1988; 34: 119–23.
Donnelly R, Elliott HL, Meredith PA, et al. Concentrationeffect relationships and individual responses to doxazosin in essential hypertension. Br J Clin Pharmacol. 1989; 28: 517–26.
Langdon CG, Packard RS. Doxazosin in hypertension: results of a general practice study in 4809 patients. Br J Clin Pract. 1994; 48: 293–8.
Vashi V, Chung M, Dias N, et al. Effect of time of administration on the pharmacokinetics and tolerance of doxazosin in healthy male volunteers. J Clin Pharmacol. 1996; 36: 325–31.
Sennello LT, Sonders RC, Glassman HN, et al. Effect of age on the pharmacokinetics of orally and intravenously administered terazosin. Clin Ther. 1988; 10: 600–7.
Somberg JC, Achari R, Laddu AR. Terazosin: pharmacokinetics and the effect of age and dose on the incidence of adverse events. Am Heart J. 1991; 122: 901–5.
Kirsten R, Weidinger G. Behandlung der essentiellen Hypertonie mit dem α-Antagonisten Bunazosin retard. Arzneimittel Forschung. 1994; 44: 13–6.
Stokes GS. Age-related effects of antihypertensive therapy with alpha-blockers. Rev J Cardiovasc Pharmacol. 1988; 12 Suppl. 8: S109–S115.
Halabi A, Nokhodian A, Kirch W. Bunazosin in patients with impaired hepatic or renal function. Eur J Drug Metab Pharmacokinet. 1993; 18: 309–13.
Chrisp P, Faulds D. Moxonidine: a review of its pharmacology, and therapeutic use in essential hypertension. Drugs. 1992; 44(6): 993–1012.
Trenk D, Wagner F, Jähnchen E, et al. Pharmacokinetics of moxonodine after single and repeated daily doses in healthy volunteers. J Clin Pharmacol. 1987; 27: 988–93.
Theodor R, Weimann H-J, Weber W, et al. Absolute bioavailability of moxonidine. Eur J Drug Metab Pharmacokinet. 1991; 16: 153–9.
Schrader J, Schoel G, Gundlach K, et al. Antihypertensive Wirkdauer und morgendlicher Blutdruckanstieg unter Moxonidin in der ambulanten 24-Stunden-Blutdruckmessung. Nieren- und Hochdruckkrankheiten. 1992; 21: 531–3.
Kirch W, Hutt HJ, Plänitz V. The influence of renal function on clinical pharmacokinetics of moxonidine. Clin Pharmacokinet. 1988; 15: 245–53.
Klink F, Endell W. Klinische Untersuchung über den Übertritt von Moxonidin vom Blut in die Muttermilch bei Hochdruck-Patientinnen. BDF Report. 1988; 200: 28–31.
Frisk-Holmberg M, Plänitz V. A selective alpha2-adrenoceptor agonist in arterial essential hypertension: clinical experience with moxonidine. Curr Ther Res Clin Exp. 1987; 42: 138–46.
Mangiameli S, Privitera A, Jonte G, et al. Moxonidine versus nifedipine retard in the treatment of mild to moderate hypertension. Z Allgemeinmed. 1992; 68: 862–6.
Ollivier JP, Christen MO, Schäfer SG. Moxonidine: a second generation of centrally acting drugs. J Cardiovasc Pharmacol. 1992; 20 Suppl. 4: S3I–S36.
Plänitz V. Intraindividual comparison of moxonidine and prazosin in hypertensive patients. Eur J Clin Pharmacol. 1986; 29: 645–50.
Plänitz V. Comparison of moxonidine and clonidine HCI in treating patients with hypertension. J Clin Pharmacol. 1987; 27: 46–51.
Prichard BNC, Simmons R, Rooks MJ, et al. A double-blind comparison of moxonidine and atenolol in the management of patients with mild to moderate hypertension. J Cardiovasc Pharmacol. 1992; 20 Suppl. 4: S45–9.
Lowenthal DT, Matzek KM, MacGregor TR. Clinical pharmacokinetics of clonidine. Clin Pharmacokinet. 1988; 14: 287–310.
Dollery CT, Davies DS, Draffan GH, et al. Clinical pharmacology and pharmacokinetics of clonidine. Clin Pharmacol Ther. 1976; 19: 11–7.
Arndts D, Doevendans J, Kirsten R, et al. New aspects of the pharmacokinetics and pharmacodynamics of clonidine in man. Eur J Clin Pharmacol. 1983; 25: 21–30.
Ramage AG. Are drugs that act both on serotonin receptors and alpha 1-adrenoreceptors more potent hypotensive agents than those that act only on alpha 1-adrenoceptors? J Cardiovasc Pharmacol 1988; 11 Suppl. 1: S30–4.
Haenni A, Lithell H. Urapidil treatment decreases plasma fibrinogen concentration in essentail hypertension. Metabolism. 1996; 45: 1221–9.
Kirsten R, Nelson K, Molz KH, et al. Pharmacodynamics and pharmacokinetics of urapidil in hypertensive patients: a crossover study comparing infusion with an infusion-capsule combination. Eur J Clin Pharmacol. 1987; 32: 61–7.
Kirsten R, Nelson K, Molz KH, et al. Influence of food intake on the bioavailability of urapidil in healthy volunteers. Int J Clin Pharmacol Ther Toxicol. 1989; 27: 298–301.
Storck J, Kirsten R. Binding of urapidil to human serum albumin: dependency on free fatty acid concentration. Int J Clin Pharmacol Ther Toxicol. 1991; 29: 204–9.
Kirsten R, Nelson K, Steinijans VW, et al. Clinical pharmacokinetics of urapidil. Clin Pharmacokinet. 1988; 14: 129–40.
Bristow MR, Gilbert EM, Abraham WT, et al. Carvedilol produces dose-related improvements in left ventricular function and survivalin subjects with chronic heart failure. Circulation. 1996; 94: 2807–16.
Yue TL, Cheng HY, Lysko PG, et al. Carvedilol, a new vasodilator and beta-adrenoceptor antagonist, is an antioxidant and free radical scavenger. J Pharmacol Exp Ther. 1992; 263: 92–8.
Sung CP, Arleth AT, Ohlstein EH. Carvedilol inhibits vascular smooth muscle cell proliferation. J Cardiovasc Pharmacol. 1993; 21: 221–7.
Hoffman BB, Lefkowitz RJ. Catecholamines, sympathomimetic drugs, and adrenergic receptor antagonists. In: Hardman JG, Limbird LE, Molinoff PB, editors. The pharmacological basis of therapeutics. 9th ed. New York: McGraw-Hill, 1996: 199–248.
Ehmer B, van der Does R, Rudorf J. Influence of carvedilol on blood glucose and glycohaemoglobin A, in non-insulin-dependent diabetics. Drugs. 1988; 36 Suppl. 6: 136–40.
Stienen U, Meyer-Sabellek W. Hemodynamic and metabolic effects of carvedilol: a metaanalysis approach. Clin Invest Med 1992; 70 Suppl.: 65–72.
Morgan T. Clinical pharmacokinetics and pharmacodynamics of carvedilol. Clin Pharmacokinet. 1994; 26: 335–46.
Deetjen A, Schaefer RM, Heidland A. Carvedilol in chronic haemodialysis patients. Hochdruck. 1992; 12: 44–5.
Neugebauer G, Akpan W, von Möllendorff E, et al. Pharmacokinetics and disposition of carvedilol in humans. J Cardiovasc Pharmacol. 1987; 10 Suppl. 11: 85–8.
Masumura H, Miki S, Kaifu Y, et al. Pharmacokinetics and efficacy of carvedilol in hypertensive patients with chronic renal failure and hemodialysis patients. J Cardiovasc Pharmacol. 1992; 19 Suppl. 1: S102–S107.
Morgan TO, Anderson A, Cripps J, et al. The use of carvedilol in elderly hypertensive patients. Eur J Clin Pharmacol 1990; 38 Suppl. 2:S129–S133.
De Mey C, Brendel E, Enterlin E. Carvedilol increases the systemic bioavailability of oral digoxin. Br J Clin Pharmacol. 1990; 29: 486–90.
Gales MA. Oral antihypertensives for hypertensive urgencies. Ann Pharmacother. 1994; 28: 352–8.
el-Quarmalawi AM, Morsy AH, al-Fadly A, et al. Labetalol vs. methyldopa in the treatment of pregnancy-induced hypertension. Int J Gynaecol Obstet. 1995; 49: 125–30.
Gold EH, Chang W, Cohen M, et al. Synthesis and comparison of some cardiovascular properties of the stereoisomers of labetalol. J Med Chem. 1988; 25: 1363–70.
Baum T, Watkins RW, Sybertz EJ, et al. Antihypertensive and hemodynamic actions of SCH 19927, the RR-isomer and labetalol. J Pharmacol Exp Ther. 1981; 218: 444–52.
Donnelly R, Macphee GJ. Clinical pharmacokinetics and kineticdynamic relationships of dilevalol and labetalol. Clin Pharmacokinet. 1991; 21: 95–109.
Kramer WG, Nagabhushan N, Affrime MB, et al. Pharmacokinetics and bioavailability of dilevalol in normotensive volunteers. J Clin Pharmacol. 1988; 28: 644–8.
McNeil JJ, Louis WJ. Clinical pharmacokinetics of labetalol. Clin Pharmacokinet. 1983; 9: 157–67.
Kelly JG, Laher MS, Donohue J, et al. The pharmacokinetics of dilevalol in renal impairment. J Hum Hypertens. 1990; 4 Suppl. 2: 59–62.
Luke DR, Awni WM, Halstenson CE, et al. Bioavailability of labetalol in patients with end-stage renal disease. Ther Drug Monit. 1992; 14: 203–8.
Rogers RC, Sibai BM, Whybrew WD. Labetalol pharmacokinetics in pregnancy-induced hypertension. Am J Obstet Gynecol. 1990; 162: 362–6.
Munshi UK, Deorari AK, Paul VK, et al. Effects of maternal labetalol on the newborn infant. Indian Pediatr. 1992; 29: 1507–12.
Haraldsson A, Geven W. Half-life of maternal labetalol in a premature infant. Pharm Weekbl Sci. 1989; 11: 229–31.
Miller K. Pharmacological management of hypertension in pediatric patients: a comprehensive review of the efficacy, safety and dosage guidelines of the available agents. Drugs. 1994; 48: 868–87.
Elliott HL, Macphee GJ, Meredith PA. The influence of age on the pharmacokinetics and antihypertensive responses to dilevalol. J Hum Hypertens. 1990; 4 Suppl. 2: 45–8.
Rocci ML, Vlasses PH, Cressman MD, et al. Pharmacokinetics and pharmacodynamics of labetalol in elderly and young hypertensive patients following single and multiple doses. Pharmacotherapy. 1990; 10: 92–9.
Macphee GJ, Howie CA, Meredith PA, et al. The effects of age on the pharmacokinetics, antihypertensive efficacy and general tolerability of dilevalol. Br J Clin Pharmacol. 1991; 32: 591–7.
Rocci ML, Valiquett T, Sirgo MA. Effects of age on the elimination of labetalol. Clin Pharmacokinet. 1989; 17: 452–7.
Duncan L, Bateman DN. Sexual function in women. Do antihypertensive drugs have an impact? Drug Saf. 1993; 8: 225–34.
Bianco S. Prevention of exercise-induced asthma by indoramin. BMJ. 1974; 4: 18.
Norbury HM, Franklin RA, Marrott PK, et al. Pharmacokinetics of oral indoramin in elderly and middle-aged female volunteers. Eur J Clin Pharmacol. 1984; 27: 247.
Pierce DM, Abrams SM, Franklin RA. Pharmacokinetics and systemic availability of the antihypertensive agent indoramin and its metabolite 6-hydroxyindoramin in healthy subjects. Eur J Clin Pharmacol. 1987; 32: 619–23.
Pierce DM, Abrams SM, Franklin RA. Intra- and inter- subject variation in the pharmacokinetics of indoramin and its 6-hydroxylated metabolite. Eur J Clin Pharmacol. 1988; 32: 195–8.
Pierce DM, Abrams SM, Franklin RA. Intra- and inter-subject variation in the pharmacokinetics of indoramin and its 6-hydroxylated metabolite. Eur J Clin Pharmacol. 1988; 35(2): 195–8.
Draffan GH, Lewis PJ, Firmin JL, et al. Pharmacokinetics of indoramin in man. Br J Clin Pharmacol. 1976; 3: 489–95.
Bauer JH, Jones LB, Gaddy P. Effects of indoramin therapy on BP, renal function, and body fluid composition. Arch Intern Med. 1984; 144: 308.
Morrison G, Spar B, Walker BR, et al. The acute and chronic effects of indoramin on renal function, hemodynamics, and transport. J Cardiovasc Pharmacol. 1986; 8 Suppl. 2: S25–29.
Krone W, Nagele H. Influence of adrenergic drugs on cholesterol metabolism. Eur J Clin Invest. 1983; 13: A17.
Shanks RG. The clinical pharmacology of indoramin. J Cardiovasc Pharmacol. 1986; 8 Suppl. 2: S8–S15.
Martinez TI, Auriemo CR, Machado AM, et al. Effects of indoramin and metoprolol on plasma lipids and lipoproteins. J Cardiovasc Pharmacol. 1986; 8 Suppl. 2: S76–S79.
Kaski JC, Araujo L, Maseri A. Effects of oxyfedrine on regional myocardial blood flow in patients with coronary artery disease. Cardiovasc Drugs Ther. 1991; 5: 991–6.
Fananapazir L, Bray C. Comparison of oxyfedrine and atenolol in angina pectoris — a double-blind study. Br J Clin Pharmacol. 1985; 20: 405–10.
Parratt JR. The hemodynamic effects of prolonged oral administration of oxyfedrine, a partial agonist at beta adrenoceptors: comparison with propranolol. Br J Pharmacol. 1974; 51: 5–13.
Schamhardt HC, Verdouw PD, van der Hoek TM, et al. Regional myocardial blood flow and segmental wall function after oxyfedrine administration in the ischaemic porcine heart. Cardiovasc Res. 1980; 14: 451–7.
Wetzelsberger N, Birkel M, Fuder H, et al. Relative bioavailability of DL-oxyfedrine HC1 after single-dose oral administration of tablets as compared to equimolar solutions. Meth Find Exp Clin Pharmacol. 1995; 17: 185–91.
Lindner J, Bauch K, Dempe A. Zur Beeinflussung des Kohlenhydrat- und Fettstoffwechsels durch Myofedrin. Medicamentum. 1980; 21: 41–5.
Scholz H. Inotropic drugs and their mechanism of action. J Am Coll Cardiol. 1984; 4: 389–97.
Borow KM, Come PC, Neumann A, et al. Physiological assessment of the inotropic, vasodilator and afterload reducing effects of milrinone in subjects without cardiac disease. Am J Cardiol. 1985; 55: 1204.
Tanaka K, Takano T. Effects of intravenous amrinone on heart failure complicated by acute myocardial infarction: comparative study with dopamine and dobutamine. Jpn Circ J. 1986; 50: 652–58.
Harada K, Ohashi K, Kumagai Y, et al. Comparison of venodilatory effect of amrinone and theophylline in human subjects. J Clin Pharmacol. 1995; 35: 1067–70.
Rocci Jr ML, Wilson H. The pharmacokinetics and pharmacodynamics of newer inotropic agents. Clin Pharmacokinet. 1987; 13: 91–109.
Edelson J, Park GB, Angellotti J, et al. Dose proportionality of amrinone. Clin Pharmacol Ther. 1983; 34: 190–4.
Steinberg C, Notterman DA. Pharmacokinetics of cardiovascular drugs in children. Inotropes and vasopressors. Clin Pharmacokinet. 1994; 27: 345–67.
Park GB, Kershner RP, Angellotti J, et al. Oral bioavailability and intravenous pharmacokinetics of amrinone in humans. J Pharm Sci. 1983; 72: 817–9.
Kullberg MP, Freeman GB, Biddlecome C, et al. Amrinone metabolism. Clin Pharmacol Ther. 1981; 29: 394–401.
Wilson H, Rocci Jr ML, Weber KT. Pharmacokinetics of oral amrinone in patients with chronic cardiac failure. Clin Pharmacol Ther. 1982; 31: 282.
Larijani GE, Rocci Jr ML, Wilson H. Protein binding of amrinone in normal volunteers and in patients with chronic cardiac failure. Drug Intell Clin Pharm. 1984; 18: 500, 1984.
Levy JH, Bailey JM. Amrinone: pharmacokinetics and pharmacodynamics. J Cardiothorac Vasc Anesth. 1989; 3: 10–4.
Hamilton RA, Kowalsky SF, Wright EM, et al. Effect of the acetylator phenotype on amrinone pharmacokinetics. Clin Pharmacol Ther. 1986; 40: 615–9.
Lawless S, Restaino I, Azin S, et al. Effect of continuous arteriovenous haemofiltration on pharmacokinetics of amrinone. Clin Pharmacokinet. 1993; 25: 80–2.
Lawless S, Burckart G, Diven W, et al. Amrinone in neonates and infants after cardiac surgery. Crit Care Med. 1989; 17: 751–4.
Allen-Webb EM, Ross MP, Pappas JB, et al. Age-related amrinone pharmacokinetics in a pediatric population. Crit Care Med. 1994; 22: 1016–24.
Harris MN, Daborn AK, O’Dwyer JP. Milrinone and the pulmonary vascular system. Eur J Anaesthes 1992; 5 Suppl.: 27–30.
Butterworth JF, Hines RL, Royster RL, et al. Apharmacokinetic and pharmacodynamic evaluation of milrinone in adults undergoing cardiac surgery. Anesthes Analges. 1995; 81: 783–92.
Bailey JM, Levy JH, Kikura M. Pharmacokinetics of intravenous milrinone in patients undergoing cardiac surgery. Anesthesiol. 1994; 81: 616–22.
Shipley JB, Tolman D, Hastillo A, et al. Review: milrinone: basic and clinical pharmacology and acute and chronic management. Am J Med Sci. 1996; 311: 286–91.
Prielipp RC, MacGregor DA, Butterworth JF, et al. Pharmacodynamics and pharmacokinetics of milrinone administration to increase oxygen delivery in critically ill patients. Chest. 1996; 109: 1291–301.
Stroshane RM, Koss RF, Biddlecome CE, et al. Oral and intravenous pharmacokinetics of milrinone in human volunteers. J Pharm Sci. 1984; 73: 1438.
Wilson H, Larijani GE, Likoff M, et al. The pharmacokinetics of milrinone in patients with chronic cardiac failure. Clin Pharmacol Ther. 1984; 35: 283.
Benotti JR, Lesko LJ, McCue JE, et al. Pharmacokinetics and pharmacodynamics of milrinone in chronic congestive heart failure. Am J Cardiol. 1985; 56: 685.
Edelson J, Stroshane RM, Benziger DP, et al. Pharmacokinetics of the bipyridines, amrinone and milrinone. Circulation. 1985; 73 Suppl. 3: 145–52.
Larsson R, Liedholm H, Andersson KE, et al. Pharmacokinetics and effects on blood pressure of a single oral dose of milrinone in healthy subjects and in patients with renal impairment. Eur J Clin Pharmacol. 1986; 29: 549–53.
Young RA, Ward A. Milrinone: a preliminary review of its pharmacological properties and therapeutic use. Drugs. 1988; 36: 158–92.
Woolfrey SG, Hegbrant J, Thysell H, et al. Dose regimen adjustment for milrinone in congestive heart failure patients with moderate and severe renal failure. J Pharm Pharmacol. 1995; 47: 651–5.
Chang AC, Atz AM, Wernovsky G, et al. Milrinone: systemic and pulmonary hemodynamic effects in neonates after cardiac surgery. Crit Care Med. 1995; 23: 1907–14.
Gilbert EM, Hershberger RE, Wiechmann RJ, et al. Pharmacological and hemodynamic effects of combined beta-agonist stimulation and phosphodiesterase inhibition in the failing human heart. Chest. 1995; 108: 1524–32.
Jondeau G, Dubourg O, Delorme G, et al. Oral enoximone as a substitute for intravenous catecholamine support in end-stage congestive heart failure. Eur Heart J. 1994; 15: 242–6.
Casella G, Cantelli I, Pavesi PC, et al. Comparative hemodynamic effects of intravenous digoxin and enoximone in severe chronic heart failure. Cardiology. 1994; 85: 303–10.
Park JW, Heinzler R, Wirtz JH, et al. Low-dose enoximone therapy in pre-transplant patients: hemodynamic, echocardiographic, and neurohumoral findings. Z Kardiol. 1994; 83 Suppl. 2: 49–53.
Hachenberg T. Enoximone in the postoperative phase of heart surgery. Z Kardiol. 1994; 83 Suppl. 2: 63–8.
el-Banayosy A, Doring B, Korner MM, et al. New avenues in therapy of postoperative low output syndrome. Zeitschr Kardiol. 1994; 83 Suppl. 2: 69–74.
Okerholm RA, Chan KY, Lang JE, et al. Biotransformation and pharmacokinetic overview of enoximone and its sulfoxide metabolite. Am J Cardiol. 1987; 60: 21c–26c.
Uretsky BF, Generalovich T, Verbalis JG, et al. MDL 17,043 therapy in severe congestive heart failure characterization of the early and late hemodynamic; pharmacokinetic, hormonal and clinical response. J Am Coll Cardiol. 1985; 5: 1414–21.
Gibelin P, Garraffo R, Sbirrazzuoli V, et al. Treatment of chronic cardiac insufficiency with intravenous bolus enoximone. Study of a pharmacokinetic-hemodynamic relation. Arch Mal Coeur Vaiss. 1990; 83: 75–81.
Dieterich HA, Lang JF, Okerholm RA, et al. Bioavailability of 150mg enoximone capsules in fasting and non-fasting conditions. Naunyn Schmiedebergs Arch Pharmacol 1986; 332 Suppl.: R93.
Mitrovic V, Petrovic O, Bahavar H, et al. Antischemic and hemodynamic effects of an oral single dose of 150 mg of the phosphodiesterase inhibitor enoximone in patients with coronary artery disease — relation to plasma concentration. Cardiovasc Drugs Ther. 1991; 5: 689–96.
Morita S, Sawai Y, Heeg JF, et al. Pharmacokinetics of enoximone after various intravenous administrations to healthy volunteers. J Pharm Sci. 1995; 84: 152–7.
Burns AM, Park GR. Prolonged action of enoximone in renal failure. Anaesthesia. 1991; 46: 864–5.
Trenk D, Jahnchen E. Clinical pharmacological aspects of therapy with enoximone. Z Kardiol. 1994; 83 Suppl. 2: 7–13.
Hausdorf G. Experience with phosphodiesterase inhibitors in pediatric cardiac surgery. Eur J Anaesthesiol 1993; 8 Suppl.: 25–30.
Innes PA, Frazer RS, Booker PD, et al. Comparison of the haemodynamic effects of dobutamine with enoximone after open heart surgery in small children. Br J Anaesth. 1994; 72: 77–81.
Zickmann B, Boldt J, Knothe C, et al. Anesthesia for heart transplantation in newborn and suckling infants. Special aspects of the hypoplastic left heart syndrome. Anaesthesist. 1995; 44: 250–6.
Dage RC, Kariya T, Hsieh CP, et al. Pharmacology of enoximone. Am J Cardiol. 1987; 60: 10C–14C.
Belz GG, Meinicke T, Schäfer-Korting M. The relationship between pharmacokinetics and pharmacodynamics of enoximone in healthy men. Eur J Clin Pharmacol. 1988; 35: 631–5.
Baumann PC, Meyer BJ, Maggiorini M, et al. Hemodynamic effects and concentration-effect relationship of a graded infusion of piroximone in patients with severe heart failure. J Cardiovasc Pharmacol. 1993; 21: 489–95.
Saal JP, Habbal R, Estagnasic P. Effects of piroximone on the right ventricular function in severe heart failure patients. Intensive Care Med. 1994; 20: 341–7.
Okerholm RA, Kecky FJ, Weiner DL, et al. The pharmacokinetics of a new cardiotonic agent, MDL 19, 205, 4-ethyl-1,3-dihydro-5-(4-pyridinyl)-2H-imidazol-2-one. FASEB J. 1983; 42: 1131.
Mitrovic V, Schmidt D, Liebrich A, et al. Hemodynamic and neurohumoral effects of the new phosphodiesterase III inhibitor piroximone in patients with heart failure. Eur Heart J 1991; 12 Suppl.: 288.
Axelroth RJ, DeMarco T, Dae M, et al. Hemodynamic and clinical evaluation of piroximone, a new inotrope-vasodilator agent, in severe congestive heart failure. J Am Coll Cardiol. 1987; 9: 1124–30.
Fauvel JP, Bernard N, Laville M, et al. Pharmacokinetics of piroximone after oral and intravenous administration to patients with renal insufficiency. Br J Clin Pharmacol. 1995; 39: 187–9.
Patel A, Caldicott LD, Skoyles JR, et al. Comparison of the haemodynamic effects of enoximone and piroximone in patients after cardiac surgery. Br J Anaesth. 1993; 71: 869–72.
Taburet AM, Schmit B. Pharmacokinetic optimisation of asthma treatment. Clin Pharmacokinet. 1994; 26: 396–418.
Jenne JW, Chick TW, Miller BA, et al. Effect of congestive heart failure on the elimination of theophylline. J Allergy Clin Immunol. 1974; 53: 80.
Piafsky KM, Sitar DS, Rangno RE, et al. Theophylline kinetics in acute pulmonary edema. Clin Pharmacol Ther. 1977; 21: 310–6.
Woo OF, Koup JR, Kramer M, et al. Acute intoxication with theophylline while on chronic therapy. Vet Hum Toxicol. 1980; 22: 48–51.
Piafsky KM, Sitar DS, Rangno RE, et al. Theophylline disposition in patients with hepatic cirrhosis. N Engl J Med. 1977; 296: 1495–7.
Staib AH, Schuppan D, Lissner R, et al. Pharmacokinetics and metabolism of theophylline in patients with liver diseases. Int J Clin Pharmacol Ther Toxicol. 1980; 18: 500–2.
Baselt RC, Albertson TE. Markedly prolonged theophylline half-life in liver failure. J Anal Toxicol. 1982; 6: 62–3.
Mühlberg W, Platt D, Bauer M, et al. Pharmakokinetik und Pharmakodynamik von Theophyllin bei multimorbiden geriatrischen Patienten. Klin Wochenschr. 1987; 65: 551–7.
Nafziger AN, Bertino JS. Sex-related differences in theophylline pharmacokinetics. Eur J Clin Pharmacol. 1989; 37: 97–100.
Zahorska-Markiewicz B, Waluga M, Zielinski M, et al. Pharmacokinetics of theophylline in obesity. Int J Clin Pharmacol Ther Toxicol. 1996; 34: 393–5.
Rizzo A, Mirabella A, Bonanno A. Theophylline pharmacokinetics after intramuscular administration. J Asthma. 1990; 27: 165–9.
Kraan J, Jonkman JH, Kroeter GH, et al. The pharmacokinetics of theophylline and enprofylline in patients with liver cirrhosis and in patients with chronic renal disease. Eur J Clin Pharmacol. 1988; 35: 357–62.
Leakey TE, Elias-Jones AC, Coates PE, et al. Pharmacokinetics of theophylline and ist metabolites during acute renal failure. A case report. Clin Pharmacokinet. 1991; 21: 400–8.
Kaukel E, Raedler A. Plasma-Theophyllin-Spiegel bei Hämodialyse-pflichtigen Patienten. Atemw Lungenkrkh. 1982; 8: 280–2.
Gardner MJ, Schatz M, Cousind L, et al. Longitudinal effects of pregnancy on the pharmacokinetics of theophylline. Eur J Clin Pharmacol. 1987; 32: 289–95.
Labovitz E, Spector SH. Placental theophylline transfer in pregnant asthmatics. JAMA. 1982; 247: 786–8.
Ruegger M, Medici TC. Astmatherapie und Schwangerschaft. Dtsch Med Wochenschr. 1984; 109: 753–4.
Reinhardt D, Richter O, Brandenburg G. Pharmacokinetics of drugs from the breast-feeding mother passing into the body of the infant, using theophylline as an example. Monatsschr Kinderheilkd. 1983; 131: 66–70.
Lee TC, Charles BG, Steer PA, et al. Theophylline population pharmacokinetics from routine monitoring data in very premature infants with apnoea. Br J Clin Pharmacol. 1996; 41: 191–200.
Haley Th J. Metabolism and pharmacokinetics of theophylline in human neonates, children, and adults. Drug Metab Rev. 1983; 14: 195–335.
Dothey CI, Tserng KY, Kaw S, et al. Maturational changes of theophylline pharmacokinetics in preterm infants. Clin Pharmacol Ther. 1989; 45: 461–8.
Sidhu J, Triggs E, Charles B, et al. Individualizing aminophylline doses in premature infants using bioelectrical impedance: a non-invasive approach. J Paediatr Child Health. 1993; 29: 113–8.
Driscoll MS, Ludden TM, Casto DT, et al. Evaluation of theophylline pharmacokinetics in a pediatric population using mixed effects models. J Pharmacokinet Biopharm. 1989; 17: 141–68.
Moore ES, Faix RG, Banagale RC, et al. The population pharmacokinetics of theophylline in neonates and young infants. J Pharmacokinet Biopharm. 1989; 17: 47–66.
Karlsson MO, Thomson AH, McGovern EM, et al. Population pharmacokinetics of rectal theophylline in neonates. Ther Drug Monit. 1991; 13: 195–200.
Berdel D, von Berg A, Reinhardt D, et al. Pharmacokinetics and pharmacodynamics of twice-daily unequal administration of theophylline retard pellets in children of various age groups. Pneumologie. 1991; 45 Suppl. 4: 863–6.
Nahata MC, Serafini D, Edwards R. Theophylline pharmacokinetics in patients with bronchopulmonary dysplasia. J Clin Pharm Ther. 1989; 14: 225–9.
Vichyanond P, Aranyanark N, Visitsuntorn N, et al. Theophylline pharmacokinetics in Thai children. Asian Pac J Allergy Immunol. 1994; 12: 137–43.
Franco TG, Powell DA, Nahata MC. Pharmacokinetics of theophylline in infants with bronchiolitis. Eur J Clin Pharmacol. 1982; 23: 123–7.
Micali G, Bhatt RH, Distefano G, et al. Evaluation of transdermal theophylline pharmacokinetics in neonates. Pharmacotherapy. 1993; 13: 386–90.
Mühlberg W, Platt D, Bauer M, et al. Pharmacokinetics and pharmacodynamics of theophylline in geriatric patients with multiple diseases. Klin Wochenschr. 1987; 65: 551–7.
Au WYW, Dutt AK, De Soyza N. Theophylline kinetics in chronic obstructive airway disease in the elderly. Clin Pharmacol Ther. 1985; 37: 472–8.
Troger U, Meyer FP Influence of endogenous and exogenous effectors on the pharmacokinetics of theophylline. Focus on biotransformation. Clin Pharmacokinet. 1995; 28: 287–324.
Upton RA. Pharmacokinetic interactions between theophylline and other medication (parts I and II). Clin Pharmacokinet. 1991; 20: 66–80, 135–50.
Nix DE, Norman A, Schentag JJ. Effect of lomefloxacin on theophylline pharmacokinetics. Antimicrob Agents Chemother. 1989; 33: 1006–8.
Ruff F, Santais MC, Callens E, et al. Effect of temafloxacin on the pharmacokinetics of theophylline. Am J Med. 1991; 91: 76S–80S.
Bratel T, Billing B, Dahlqvist R. Felodipine reduces the absorption of theophylline in man. Eur J Clin Pharmacol. 1989; 36: 481–5.
Charansonney OL, Spriet A. Pentoxifylline and intermittent claudication: critical analysis of clinical trials. Review Therapie. 1995; 50: 73–8.
Ernst E. Pentoxifylline for intermittent claudication: a critical review. Angiology. 1994; 45: 339–45.
Scheffler P, de la Hamette D, Gross J, et al. Intensive vascular training in stage IIb of peripheral arterial occlusive disease: the additive effects of intravenous pentoxifylline during training. Circulation. 1994; 90: 818–22.
Koretsune Y, Kodama K, Nanto S, et al. Acute effects of intravenous trapidil on hemodynamics, coronary circulation and myocardial metabolism in man. Jpn Circ J. 1983; 47: 391–9.
Kawamura T, Kitani T, Okajima Y, et al. Effect of trapidil on prostacyclin generation of arterial wall. Prostaglandins Med. 1980; 5: 113–21.
Weiss M, Sziegoleit W, Pönicke K, et al. Bioavailability of trapidil tablets. Drugs Exp Clin Res. 1989; 39: 1137–8.
Gehrke A, Leidreiter B, Bornschein I. Zur Serumproteinbindung von Trapidil. Pharmazie. 1976; 31: 579–80.
Nieder J, Claus P, Augustin W. Effect of trapidil in prevention of pre-eclampsia and fetal retardation. Zentralbl Gynaekol. 1995; 117: 23–8.
Krause W, Krais Th. Pharmacokinetics and pharmacodynamics of the prostacyclin analogue iloprost in man. Eur J Clin Pharmacol. 1986; 30: 61–8.
Krause W, Krais Th. Pharmacokinetics and pharmacodynamics of radio-labeled Iloprost in elderly volunteers. Eur J Clin Pharmacol. 1987; 32: 597–605.
Hildebrand M, Krause W, Oberender HA, et al. Pharmacokinetics of iloprost in patients with severe peripheral arterial occlusive disease. Eicosanoids. 1990; 3: 145–8.
Hildebrand M, Krause W, Fabian H, et al. Pharmacokinetics of iloprost in patients with chronic renal failure and on maintenance haemodialysis. Int J Clin Pharmacol Res. 1990; 10: 285–92.
Hildebrand M, Krause W, Angeli P, et al. Pharmacokinetics of iloprost in patients with hepatic dysfunction. Int J Pharmacol Ther Toxicol. 1990; 28: 430–4.
Schror K. Aspirin and platelets: the antiplatelet action of aspirin and its role in thrombosis treatment and prophylaxis. Semin Thromb Hemost. 1997; 23(4): 349–56.
Scheffler P, de la Hamette D, Leipnitz G. Therapeutic efficacy of intravenously applied prostaglandin E1. Vasa 1989; 28 Suppl.: 19–25.
Golub M, Zia P, Matsuno M, et al. Metabolism of prostaglandin A1 and E1 in man. J Clin Invest. 1975; 56: 1404–10.
Creutzig A, Caspary L. Prostanoids in therapy of peripheral arterial occlusive disease. Therapie. 1991; 46: 241–5.
Heidrich H, Breddin HK, Rudofsky G, et al. Cardiopulmonary effects and safety of prostaglandin E1: a review. Int J Angiol. 1994; 3: 160–8.
Rudofsky G. Intravenöse und intraarterialle Prostaglandin E1 Behandlung bei Patienten im Stadium IIb einer arteriellen Verschlußkrankheit. Vasa 1988; 23 Suppl.: 121.
Thadani U. Role of nitrates in angina pectoris. Am J Cardiol. 1992; 70: 43B–53B.
Unger P, Leone A, Staroukine M, et al. Hemodynamic response to molsidomine in patients with ischemic cardiomyopathy tolerant to isosorbide dinitrate. J Cardiovasc Pharmacol. 1991; 18: 888–94.
Wagner F, Gohlke-Bärwoff C, Trenk D, et al. Differences in the antiischaemic effects of molsodomine and isosorbide dinitrate (ISDN) during acute and short-term administration in stable angina pectoris. Eur Heart J. 1991; 12: 994–9.
Engelmann L, Gottschild D. Zum hämodynamischen Wirkungsprofil von Pentaerytrithyltetranitrat. Z Gesamte Inn Med. 1981; 36: 244–6.
Bultas J, Karetova D. Does chronic nitrate therapy induce tolerance to short-acting ones? Sbornik Lekarsky. 1993; 94: 71–5.
Oates JA. Antihypertensive agents and the drug therapy of hypertension. In: Hardman JG, Limbird LE, Molinoff PB, et al., editors. The pharmacological basis of therapeutics. 9th ed. New York: McGraw-Hill, 1996: 781–808.
Bogaert MG. Pharmacokinetics of organic nitrates in man: an overview. Eur Heart J 1988; 9 Suppl. A: 33–7.
Bogaert MG. Clinical pharmacokinetics of organic nitrates. Clin Pharmacokinet. 1983; 8: 410–21.
Vogt D, Trenk D, Bonn R, et al. Pharmacokinetics and haemodynamic effects of ISDN following different dosage forms and routes of administration. Eur J Clin Pharmacol. 1994; 46: 319–24.
Taylor T, Chasseaud LF, Doyle E, et al. Isosorbide dinitrate pharmacokinetics. Drug Res. 1982; 32: 1329–33.
Bogaert MG, Rosseel MT, Boelaert J, et al. Fate of isosorbide dinitrate and mononitrates in patients with renal failure. Eur J Clin Pharmacol. 1981; 21: 73–6.
Bauer H, Laufen H, Franz HE. Isosorbide dinitrate in plasma and dialysate during haemodialysis. Eur J Clin Pharmacol. 1986; 30: 187–90.
Bogaert MG, Rosseel MT, Elewaut A. Fate of orally given isosorbide dinitrate in cirrhotic patients. Int J Clin Pharmacol Ther Toxicol. 1984; 22: 491–2.
Bogaert MG, Rosseel MT. Fate of orally given isosorbide dinitrate in man: factors of variability. Z Kardiol. 1983; 72 Suppl. 3: 11–3.
Schneeweiss A, Weiss M. Advances in nitrate therapy. 2nd ed. Berlin: Springer, 1990.
Abshagen U. Pharmacokinetics of isosorbide mononitrate. Am J Cardiol. 1992; 70: 61G–66G.
Fung HL. Pharmacokinetics and pharmacodynamics of organic nitrates. Am J Cardiol. 1987; 60: 4H–9H.
Taylor T, Taylor IW, Chassseaud LF, et al. Pharmacokinetics and metabolism of organic nitrate vasodilators. Prog Drug Metabolism. 1987; 10: 207–336.
Evers J, Krakamp B, Klimkait W, et al. Pharmacokinetics of 5-ISMN in renal insufficiency. Herz/Kreisl 1984; 16 Suppl.: 9–12.
Evers J, Krakamp B, Klimkait W, et al. Pharmacokinetics of isosorbide-5-nitrate in renal failure. Eur J Clin Pharmacol. 1986; 30: 349–50.
Evers J, Bonn R, Boertz A, et al. Pharmacokinetics of isosorbide-5-nitrate during haemodialysis and peritoneal dialysis. Eur J Clin Pharmacol. 1987; 32: 503–5.
Steudel HC, Volkenandt M, Steudel AT. Pharmacokinetics of isosorbide-5-mononitrate after oral and intravenous administration in patients with liver cirrhosis. Z Kardiol. 1983; 72 Suppl. 3: 24–8.
Akpan W, Endele R, Neugebauer G, et al. Pharmacokinetics of IS-5-MN after oral and intravenous administration in patients with hepatic failure. In: Cohn JN, Rittinghausen R, editors. Mononitrates. Berlin: Springer, 1985; 86–91.
Nakashima E, Rigod JF, Lin ET, et al. Pharmacokinetics of nitroglycerin and its dinitrate metabolites over a thirtyfold range of oral doses. Clin Pharmacol Ther. 1990; 47: 592–8.
Abshagen U. Clinical pharmacology of antianginal drugs. In: Abshagen U, editor. Handbook of experimental pharmacology. Vol. 76. Berlin, Heidelberg: Springer Verlag, 1985.
Kwon HR, Green P, Curry SH. Pharmacokinetics of nitroglycerin and ist metabolites after administration of sustainedrelease tablets. Biopharm Drug Dispos. 1992; 13: 141–52.
Thadani U, Whitsett T. Relationship of pharmacokinetic and pharmacodynamic properties of the organic nitrates. Clin Pharmacokinet. 1988; 15: 32–43.
Abrams J. Update on nitroglycerin and nitrates. Drug Ther. 1992; 67: 82–4.
Habbab MA, Haft JA. Heparin resistance induced by intravenous nitroglycerin. Arch Intern Med. 1987; 147: 857–60.
Pizzulli L, Nitsch J, Lüderitz B. Hemmung der Heparinwirkung durch Glyceroltrinitrat. Dtsch Med Wochenschr. 1988; 113: 1837–40.
Gonzalez ER, Jones HD, Graham S, et al. Assessment of the drug interaction between intravenous nitroglycerin and heparin. Ann Pharmacother. 1992; 26: 1512–4.
Berk SI, Grunwald A, Pal S, et al. Effect of intravenous nitroglycerin on heparin dosage requirements in coronary artery disease. Am J Cardiol. 1993; 72: 393–6.
Bassenge E. Pharmakologische Basis der Therapie mit Molsidomin. Herz. 1982; 5: 296–306.
Schulz W, Kober G, Bernauer R, et al. Active and passive changes in coronary diameter after vasodilation with SIN-1, the active metabolite of molsidomine. Am Heart J. 1985; 109: 694–9.
Chassoux G. Molsidomine and lipid metabolism J Cardiovasc Pharmacol 1989; 14 Suppl. 11: S137–8.
Rosenkranz B, Winkelmann BR, Parnham MJ. Clinical pharmacokinetics of molsidomine. Clin Pharmacokinet. 1996; 30: 372–84.
Bergstrand R, Vedin A, Wilhelmsson C, et al. Intravenous and oral administration of molsidomine, a pharmacodynamic and pharmacokinetic study. Eur J Clin Pharmacol. 1984; 27: 203–8.
Ostrowski J, Gaul G, Voegele D, et al. Pharmacokinetics of an extended-release dosage form of molsidomine in patients with coronary heart disease. Eur J Clin Pharmacol. 1985; 28: 611–3.
Meinertz T, Brandstätter A, Trenk D, et al. Relationship between pharmacokinetics and pharmacodynamics of molsidomine and its metabolites in humans. Am Heart J. 1985; 109: 644–8.
Spreux-Varoquaux O, Doll J, Grandjean N, et al. Pharmacokinetics of molesidomine and its active metabolite, linsidomine, in patients with liver cirrhosis. Br J Clin Pharmacol. 1991; 32(3): 399–401.
Wiemer M, Pizzulli L, Reichert H, et al. Gibt es eine Wechselwirkung zwischen Heparin und Molsidomin? Z Kardiol 1992; 81 Suppl. 1: 104.
Kojda G, Stein D, Kottenberg E, et al. In vivo effects of pentaerythrityl-tetranitrate and isosorbide-5-mononitrate on the development of atherosclerosis and endothelial dysfunction in cholesterol-fed rabbits. J Cardiovasc Pharmacol. 1995; 25: 763–73.
Schneider HT, Stalleicken D. Pentaerithrityltetranitrat. Darmstadt: Steinkopf Verlag, 1995.
Weber W, Michaelis K, Luckow V, et al. Pharmacokinetics and bioavailability of pentaerithrityl tetranitrate and two of its metabolites. Drug Res. 1995; 45: 781–4.
Haustein KO, Winkler U, Löffler A, et al. Absorption and bioavailability of pentaerithrityl-tetranitrate. Int J Clin Pharmacol Ther Toxicol. 1995; 33: 95–102.
Ivankovich AD, Braverman B, Stephens TS, et al. Sodium thiosulfate in humans: relation to sodium nitroprusside toxicity. Anesthesiology. 1983; 58: 11–7.
Schulz V. Clinical pharmacokinetics of nitroprusside, cyanide, thiosulphate and thiocyanate. Clin Pharmacokinet. 1984; 9: 239–51.
Bodigheimer K, Nowak F, Schoenborn W. Pharmacokinetics and thyrotoxicity of the sodium nitroprusside metabolite thiocyanate. Dtsch Med Wochenschr. 1979; 104: 939–43.
Kirsten R, Nelson K, Kirsten D, et al. Clinical pharmacokinetics of vasodilators: part I. Clin Pharmacokinet. 1998; 34: 457–82.
Urquhart J. A call for a new discipline. Pharm Technol. 1987; 11: 16–7.
Girvin B, Johnston GD. The implications of noncompliance with antihypertensive medication. Drugs. 1996; 52: 186–95.
Hirschl MM. Guidelines for the drug treatment of hypertensive crises. Drugs. 1995; 50: 991–1000.
Müller FB, Laragh JH. Issues, goals, and guidelines for choosing first-line and combination antihypertensive drug therapy. In: Hypertensive pathophysiology, diagnosis, and management. Laragh JH, Brenner BM, editors. New York: Raven Press Ltd, 1990: 2107–15.
Roccella EJ, For the National High Blood Pressure Education Program Working Group on Hypertension Control in Children and Adolescents. Update on the 1987 task force report on high blood pressure in children and adolescents: a working group report from the national high blood pressure education program. Pediatrics. 1996; 98: 649–58.
Okada M, Inoue H, Nakamura Y, et al. Excretion of diltiazem in human milk. N Engl J Med. 1985; 312: 992–3.
Begg EJ, Atkinson HC, Darlow BA. Guide to safety of drugs in breastfeeding. In: Speight TM, Holford NHG, editors. Averys Drug Treatment. 4th ed. Auckland: Adis International Press, 1997: 1701–23.
Ellsworth A. Pharmacotherapy of hypertension while breastfeeding. J Hum Lact. 1994; 10: 121–4.
Campbell N, Paddock V, Sundaram R. Alteration of methyldopa absorption, metabolism, and blood pressure control caused by ferrous sulphate and ferrous glucuronate. Clin Pharmacol Ther. 1988; 43: 381–6.
Knott C. The treatment of hypertension in pregnancy: clinical pharmacokinetic considerations. Clin Pharmacokinet. 1991; 21: 233–41.
Boutroy MJ, Vert P, de Ligny BH, et al. Captopril administration in pregnancy impairs fetal angiotensin converting enzyme activity and neonatal adaptation. Lancet. 1984; 2: 935–6.
Fiochi R, Lijnen P, Fagard R, et al. Captopril during pregnancy. Lancet. 1984; 2: 1153.
Lindheimer MD, Katz AI. Preeclampsia: pathophysiology, diagnosis, and management. Ann Rev Med. 1989; 40: 233–50.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Kirsten, R., Nelson, K., Kirsten, D. et al. Clinical Pharmacokinetics of Vasodilators. Clin Pharmacokinet 35, 9–36 (1998). https://doi.org/10.2165/00003088-199835010-00002
Published:
Issue Date:
DOI: https://doi.org/10.2165/00003088-199835010-00002